Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding αvβ3 integrins

Contrast Media and Molecular Imaging

Volumn 8, Issue 4, 2013, Pages 350-360

  Conti, Laura ^a   Lanzardo, Stefania ^a   Iezzi, Manuela ^b   Montone, Monica ^a   Bolli, Elisabetta ^a   Brioschi, Chiara ^c   Maiocchi, Alessandro ^c   Forni, Guido ^a   Cavallo, Federica ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Bracco Imaging SpA   (Italy)

Author keywords

v 3 integrin; BALB neuT mice; Mammary cancer; Optical imaging; RGD

Indexed keywords

AMINO ACID; ARGININE; ASPARTIC ACID; CD24 ANTIGEN; DA364 PROBE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCINE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER DIAGNOSIS; CANCER SIZE; CARCINOMA IN SITU; CONTROLLED STUDY; EARLY DIAGNOSIS; EX VIVO STUDY; FEMALE; FLUORESCENCE IMAGING; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MAMMARY GLAND; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PALPATION; PRECANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; VACCINATION;

ANIMALS; CARBOCYANINES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; INTEGRIN ALPHAVBETA3; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PEPTIDES, CYCLIC; RECEPTOR, ERBB-2;

EID: 84876883301     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1529     Document Type: Article

References (39)

1. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003; 9(11): 4227-4239.
2. Carver BS, Pandolfi PP. Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 2006; 12(18): 5305-5311.
3. de Jong M, Maina T. Of mice and humans: are they the same? - Implications in cancer translational research. J Nucl Med 2010; 51(4): 501-504.
4. Sokolov K, Aaron J, Hsu B, Nida D, Gillenwater A, Follen M, MacAulay C, Adler-Storthz K, Korgel B, Descour M, Pasqualini R, Arap W, Lam W, Richards-Kortum R. Optical systems for in vivo molecular imaging of cancer. Technol Cancer Res Treat 2003; 2(6): 491-504.
5. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264(5158): 569-571.
6. Costouros NG, Diehn FE, Libutti SK. Molecular imaging of tumor angiogenesis. J Cell Biochem Suppl 2002; 39: 72-78.
7. Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, Bading JR, Laug WE, Conti PS. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imag 2004; 31(8): 1081-1089.
8. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G, Robertson JD, Wickline SA, Lanza GM. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med 2005; 53(3): 621-627.
9. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 2004; 15(1): 41-49.
10. Cai W, Sam Gambhir S, Chen X. Multimodality tumor imaging targeting integrin alphavbeta3. Biotechniques 2005; 39(6 suppl): S14-25.
11. Bowden DJ, Barrett T. Angiogenesis imaging in neoplasia. J Clin Imag Sci 2011; 1: 38.
12. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET Imaging of Integrin alphaVbeta3 Expression. Theranostics 2011; 1: 48-57.
13. Lanzardo S, Conti L, Brioschi C, Bartolomeo MP, Arosio D, Belvisi L, Manzoni L, Maiocchi A, Maisano F, Forni G. A new optical imaging probe targeting alphaVbeta3 integrin in glioblastoma xenografts. Contrast Media Mol Imag 2011; 6(6): 449-458.
14. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998; 188(3): 589-596.
15. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004; 64(8): 2858-2864.
16. Rolla S, Ria F, Occhipinti S, Di Sante G, Iezzi M, Spadaro M, Nicolo C, Ambrosino E, Merighi IF, Musiani P, Forni G, Cavallo F. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J Immunol 2010; 184(11): 6124-6132.
17. Rodenhiser DI, Andrews JD, Vandenberg TA, Chambers AF. Gene signatures of breast cancer progression and metastasis. Breast Cancer Res 2011; 13(1): 201.
18. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006; 90: 175-213.
19. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165(9): 5133-5142.
20. Morrison B, Cutler ML. The contribution of adhesion signaling to lactogenesis. J Cell Commun Signal 2010; 4(3): 131-139.
21. Lee JH, Kim SH, Lee ES, Kim YS. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep 2009; 22(5): 1149-1156.
22. Baluk P, McDonald DM. Markers for microscopic imaging of lymphangiogenesis and angiogenesis. Ann NY Acad Sci 2008;1131:1-12.
23. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10(1): 9-22.
24. Kang JH, Chung JK. Molecular-genetic imaging based on reporter gene expression. J Nucl Med 2008; 49(suppl 2): 164S-179S.
25. Pannellini T, Forni G, Musiani P. Immunobiology of her-2/neu transgenic mice. Breast Dis 2004; 20: 33-42.
26. Arigoni M, Barutello G, Lanzardo S, Longo D, Aime S, Curcio C, Iezzi M, Zheng Y, Barkefors I, Holmgren L, Cavallo F. A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. Angiogenesis 2012; 15(2): 305-316.
27. Curcio C, Khan AS, Amici A, Spadaro M, Quaglino E, Cavallo F, Forni G, Draghia-Akli R. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther 2008; 15(2): 108-114.
28. Porzia A, Lanzardo S, Citti A, Cavallo F, Forni G, Santoni A, Galandrini R, Paolini R. Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J Immunol 2010; 184(8): 4170-4177.
29. Boggio K, Di Carlo E, Rovero S, Cavallo F, Quaglino E, Lollini PL, Nanni P, Nicoletti G, Wolf S, Musiani P, Forni G. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 2000; 60(2): 359-364.
30. Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, De Giovanni C, Montani M, Lollini PL, Masucci G, Forni G, Cavallo F. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010; 70(7): 2604-2612.
31. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62(1): 10-29.
32. Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet 2011;378(9805):1804-1811.
33. Singh V, Saunders C, Wylie L, Bourke A. New diagnostic techniques for breast cancer detection. Future Oncol 2008; 4(4): 501-513.
34. Gibson AP, Hebden JC, Arridge SR. Recent advances in diffuse optical imaging. Phys Med Biol 2005; 50(4): R1-43.
35. van de Ven S, Wiethoff A, Nielsen T, Brendel B, van der Voort M, Nachabe R, Van der Mark M, Van Beek M, Bakker L, Fels L, Elias S, Luijten P, Mali W. A novel fluorescent imaging agent for diffuse optical tomography of the breast: first clinical experience in patients. Mol Imag Biol 2010; 12(3): 343-348.
36. Ueda S, Roblyer D, Cerussi A, Durkin A, Leproux A, Santoro Y, Xu S, O'Sullivan TD, Hsiang D, Mehta R, Butler J, Tromberg BJ. Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Cancer Res 2012; 72: 4318-4328.
37. Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, Lowik CW, Frangioni JV, van de Velde CJ, Vahrmeijer AL. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol 2011; 104(3): 323-332.
38. Conti L, Regis G, Longo A, Bernabei P, Chiarle R, Giovarelli M, Novelli F. In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. Blood 2007; 109(6): 2496-2504.
39. Street SE, Zerafa N, Iezzi M, Westwood JA, Stagg J, Musiani P, Smyth MJ. Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res 2007; 67(11): 5454-5460.